SCHEMBL4864909

SCHEMBL4864909

O=c1c([N+](=O)[O-])c(-c2cnn(Cc3ccccc3F)c2)n(C(F)c2ccccc2)c(=O)n1C(F)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 9/20 0.43
ADORA2A P29274 6/20 0.43
ADORA1 P30542 6/20 0.43
PKM P14618 2/20 0.40
MAPT P10636 2/20 0.40
ALDH1A1 P00352 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
SCD O00767 1/20 0.37
SCD5 Q86SK9 1/20 0.37
ALK Q9UM73 1/20 0.36
PKLR P30613 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2C19 P33261 1/20 0.34
GAA P10253 1/20 0.34
GNRHR P30968 1/20 0.33
CREBBP Q92793 1/20 0.33
KCNH2 Q12809 1/20 0.32
GRIN2B Q13224 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4916172 0.88 ADORA2B (0.45) ADORA2BADORA2AADORA1ALDH1A1SCD5
SCHEMBL4858900 0.88 ADORA2B (0.44) ADORA2BADORA2AADORA1PKMMAPT
SCHEMBL4866693 0.85 ADORA2A (0.38) ADORA2BADORA2AADORA1MAPTALDH1A1
SCHEMBL4867554 0.83 ADORA2B (0.45) ADORA2BADORA2AADORA1PKMMAPT
SCHEMBL4764062 0.83 MAPT (0.37) ADORA2BADORA2AADORA1PKMMAPT
SCHEMBL4764058 0.83 MAPT (0.37) ADORA2BADORA2AADORA1PKMMAPT
SCHEMBL4864902 0.81 ADORA2B (0.49) ADORA2BADORA2AADORA1PKMMAPT
SCHEMBL4865952 0.81 ADORA2B (0.41) ADORA2BADORA2AADORA1PKMMAPT
SCHEMBL4866434 0.80 BRD4 (0.38) PKMALDH1A1CREBBP
SCHEMBL4862902 0.79 HSP90AA1 (0.47) ADORA2BADORA2AADORA1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7449473-B2 Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists CV THERAPEUTICS, INC. (US) 2008-11-11 US disclosed
EP-1678181-A2 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2006-07-12 EP disclosed
US-20050119287-A1 A2B adenosine receptor antagonists GILEAD PALO ALTO, INC. 2005-06-02 US disclosed
WO-2005042534-A2 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119287-A1 A2B adenosine receptor antagonists ADORA2B, ADORA2A, ADORA3 ADORA2B 1/4885ADORA2A 2/4885ADORA1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.